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Abstract
Purpose: To investigate whether time-trends of enhanced [18F]Fluoromethylcholine ([18F]FCH) in lymph nodes (LN) of
prostate cancer (PCa) patients can help to discriminate reactive from malignant ones, and whether single time point
standardized uptake value (SUV) measurements also suffice.
Procedures: 25 PCa patients with inguinal (presumed benign) and enlarged pelvic LN (presumed malignant) showing
enhanced [18F]FCH uptake at dual-phase PET-CT were analyzed. Associations between LN status (benign versus malignant)
and SUVmax and SUVmeanA50, determined at 2 min (early) and 30 min (late) post injection, were assessed. We considered two
time-trends of [18F]FCH uptake: type A (SUV early . SUV late) and type B (SUV late $ SUV early). Histopathology and/or
follow-up were used to confirm the assumption that LN with type A pattern are benign, and LN with type B pattern
malignant.
Results: Analysis of 54 nodes showed that LN status, time-trends, and ‘late’ (30 min p.i.) SUVmax and SUVmeanA50 parameters
were strongly associated (P,0.0001). SUVmax relative difference was the best LN status predictor. All but one inguinal LN
showed a decreasing [18F]FCH uptake over time (pattern A), while 95% of the pelvic nodes presented a stable or increasing
uptake (pattern B) type.
Conclusions: Time-trends of enhanced [18F]FCH uptake can help to characterize lymph nodes in prostate cancer patients.
Single time-point SUV measurements, 30 min p.i., may be a reasonable alternative for predicting benign versus malignant
status of lymph nodes, but this remains to be validated in non-enlarged pelvic lymph nodes.
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Introduction
Choline-based PET has proven value in several neoplasms, and
especially in prostate cancer [1,2]. [18F]FCH PET-CT seems to
become a useful imaging tool to solve the clinical problem of rising
serum prostate-specific antigen (PSA) after initially treated prostate
cancer [3–5], with PET-CT sensitivity being proportionally
related to the PSA level [6,7].
Choline is the precursor of phosphatidylcholine (PC), an
essential phospholipid of cell membranes. The phosphorylation
process is catalyzed by choline kinase (CK) [2]. In prostate cancer,
enhanced choline uptake is explained by both increased mitogenic
activity as well as up regulation of CK [8]. However, the signal is
not tumor specific [9,10]. Since biopsy of presumed regional
lymph node metastases is often not trivial due to their localization
in prostate cancer, false positive readings may induce serious
problems in the clinical context.
Both [18F] and [11C]-labeled choline derivates have been
developed and studied as possible metabolic imaging tools in the
detection of primary PCa, regional LN and distant metastases
[11,12]. The main advantages of [18F] over [11C]-labeled tracers
are the longer half-life (110 min versus 20 min) and a better spatial
resolution due to the shorter positron range of 18F. However,
[18F]choline is excreted in urine [13] and this can compromise the
interpretation of the pelvic area. Since [18F]FCH is rapidly cleared
from the blood pool, acquisition protocols have been designed
with imaging of the pelvis prior to bladder filling (within minutes
after injection), followed by a whole body scan after e.g. 30 min
[1,14–16] – the dual-phase protocol. Patterns of tracer uptake as a
function of time have shown to be helpful in discriminating
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intraprostatic tracer uptake [8,15] as well as sites of suspected
haematogeneous metastases [17].
It was suggested that increasing or stable [18F]FCH uptake over
time (3–7 min versus 30–60 min after injection) was compatible
with malignancy, while a decreasing tracer uptake is associated
with benign status [8,15,17]. For lymph node assessment this
hypothesis has not been validated. Beheshti et al. [8] described an
interesting early [18F]FCH wash-out pattern of false-positive LN in
the preoperative setting of 130 patients with high and intermediate
risk for disseminated prostate cancer. This phenomenon was
deemed highly important for the differentiation of malignant
versus benign nodes. However, the study could not support this
finding with a statistically relevant number of lesions.
In the present study we investigated whether time-trends of
enhanced [18F]FCH uptake in lymph nodes can help to
discriminate between benign and malignant sites, and we explored
whether single time point SUV measurements may also suffice.
Materials and Methods
Patients
Formal ethical approval for performing this retrospective study
was obtained from the Medical Ethics Committee of the VU
University Medical Center, Amsterdam, The Netherlands (ap-
proval date June 2012, reference 2012/254). This approval states
that written informed consent from participants is wavered since
the study does not fall within the scope of the Medical Research
Involving Human Subjects Act (section 16.2 WMO, 26th February
1998).
We retrospectively studied [18F]FCH PET-CT scans of 66
consecutive patients with prostate cancer (median age, 63 years;
range, 50–80 years), performed at the VU University Medical
Center, Amsterdam, The Netherlands, between January 2009 and
March 2011. Three main clinical indications (I) for PET-CT were:
I1. PSA relapse in previously treated PCa (n= 39); I2. newly
diagnosed PCa (n = 16) and I3. staging of patients with suspected
oligometastases (typically skeletal, identified with other imaging
modalities), in newly diagnosed or already treated PCa (n = 11).
Patient characteristics [age, Gleason score (Gl), serum PSA at
diagnosis and at the time of performing the PET-CT] were
gathered, including the date and the type of previous therapy [e.g.
radical prostatectomy (RP), external-beam radiation therapy
(EBRT), brachytherapy (BT), pelvic lymph node dissection
(PLND), anti-androgen therapy (ADT) or the combination of
these].
Inclusion criteria were: dual-phase [18F]FCH PET-CT per-
formed in patients with histopathologically proven PCa; enhanced
[18F]FCH uptake in any inguinal nodes and in pelvic LN with a
short axis diameter $8 mm, visible at early and/or late PET scan.
Patients with multiple malignancies (e.g. one or more other types
of carcinoma apart from the PCa) were excluded.
PSA relapse, suspected to be associated with residual or
recurrent disease, was defined as a serum concentration level
above 0.2 ng/ml, after RP and after the combination of RP with
other types of therapy. A rising PSA level .2 ng/ml above the
nadir value in patients treated by means of EBRT was considered
suspect for persistent or recurrent disease [18]. Increased serum
PSA was confirmed by two consecutive exams for all patients. The
maximal time interval between performing the PET-CT scan and
the last PSA determination was 14 days.
Based on histology, the primary PCa was classified as low (Gl
,7), intermediate (Gl = 7) and high grade (Gl.7), according to the
modified Gleason Grading System [19].
Lymph Node Classification
We classified lymph nodes as benign or malignant using the
following approach: inguinal lymph nodes with enhanced
[18F]FCH uptake were considered benign since the prostatic
lymph node drainage pattern does not include inguinal nodes [20–
22]. Pelvic nodes with a short axis diameter $8mm were classified
as malignant [23]. Additional confirmation was obtained using
histopathology (whenever feasible), and with clinical follow-up of
6–12 months in all patients. Follow-up consisted of PSA
measurements over time (as above mentioned) and/or evaluation
of other imaging (i.e., contrast-enhanced abdominopelvic CT,
Table 1. Patient characteristics.
Total patients (N=25) Pelvic group (N=17)
Combined pelvic &
inguinal (N=1) Inguinal group (N=7)
Mean age (years) 63 (range: 50–80) 63 63 (range: 57–68)
Mean serum PSA (ng/ml) at diagnosis 51 27 18
Mean serum PSA (ng/ml) at PET time 38 37 17
Gleason score (number of patients)
,7 4 – 2
7 7 – 4
.7 6 1 1
Previous therapy: number of patients (indication)
EBRT (6ADT 6PLND) 5 (36I1+26I3) – 2 (26I1)
EBRT + RP 2 (26I1) – 1 (I1)
RP 1 (I1) – 2 (26I1)
ADT 1 (I1) – 1 (I3)
BT 1 (I1) – –
NA 7 (76I2) 1 (I3) 1 (I2)
N number, EBRT external -beam radiation therapy, ADT anti-androgen therapy, PLND pelvic lymph node dissection, RP radical prostatectomy, BT brachytherapy, NA not
applicable, I1: PSA relapse after therapy, I2: newly diagnosed prostate cancer, I3: staging patients with suspected oligometastases from prostate cancer.
doi:10.1371/journal.pone.0048430.t001
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pelvic MRI). We applied the following radiological criteria to
classify change [24]: an increase by 30% versus initial size as
progression, a decrease by 30% as regression, and intermediate
values or no change in size as stable.
Therefore, malignancy was defined as a positive histopatholog-
ical result; radiologically confirmed progression in size of the
pertaining lymph nodes; decrease or normalization of serum PSA
and radiological response after therapy, providing these were the
only abnormal findings on the initial PET-CT scan; decrease or
normalization of serum PSA with nodal regression after RT, with
the RT field including the site of the suspected LN.
Synthesis of [18F]FCH
[18F]FCH was synthesized according to the methods proposed
by DeGrado et al. [1,25] and Iwata et al. [26], with minor
modifications and by use of automated modules built in-house
[27]. In short, cyclotron produced [18F]fluoride was reacted with
dibromomethane, the formed [18F]fluorobromomethane was
purified and used in the alkylation of 2-(dimethylamino)ethanol
to obtain 2.660.9 GBq [18F]FCH after semi-preparative high
performance liquid chromatography (HPLC) purification, refor-
mulation in aqueous 0.9% NaCl and sterile filtration.
The radiochemical purity was .99.5% and no chemical
impurities were detected as assessed by analytical radio/ultra-
violet-HPLC (UV-HPLC). Residual concentrations of dibromo-
methane (0–8 ppm) and 2-(dimethylamino)ethanol (95640 ppm)
were determined by flame ionization detector - gas chromatog-
raphy (FID-GC). Absence of bacterial endotoxins in the product
was confirmed by an Endosafe portable test system (PTS) reader
(Charles River) and all samples were tested for sterility.
PET-CT Imaging
All studies were performed on a Gemini TOF-64 PET-CT
scanner (Philips Medical Systems, Best, The Netherlands) with an
axial field per view of 18 cm. Low-dose CT (LD-CT) was collected
using a beam current of 30 to 50 mAs at 120 keV. CT was
reconstructed using an image matrix size of 5126512 resulting in
voxel sizes of 1.1761.17 mm and a slice thickness of 5 mm. For
PET, data were reconstructed by means of a raw action ordered
subset expectation maximization algorithm using default recon-
struction parameters. Time of flight (TOF) information was used
during reconstruction. Reconstructed images had an image matrix
size of 1446144, a voxel size of 464 mm and a slice thickness of
5 mm.
All patients underwent the standard [18F]FCH image acquisi-
tion protocol at our institution: following the LD-CT, ‘early’ PET
image acquisition started 2 min after intravenous injection of
4 MBq/kg [18F]FCH, using a 35 cm scan trajectory over the
pelvic region (2 min/bed position); patients were asked to void
20 min post injection (p.i.), and at 30 min p.i. a ‘late’ whole body
PET sequence was started, from mid-thigh to the skull vertex,
again using 2 min acquisitions/bed position. Patient preparation
was similar to that required for FDG PET [28].
PET-CT Data Analysis
PET-CT images were evaluated by an experienced nuclear
medicine specialist who first identified all lymph nodes with
enhanced FCH uptake versus their direct background (on early
and/or late scan time points) within the field of view of the early
scan trajectory. Lymph node diameters were measured using the
CT component of the PET-CT scanner, and standard CT and
MRI, where available.
PET and LD-CT images were converted to ECAT 7 format
and regions of interest (ROIs) were semi-automatically drawn
around every pelvic LN that met the inclusion criteria mentioned
above, using in-house developed software, as previously described
[29,30]. For lesion delineation, we used the adaptive threshold of
50% of maximum voxel value within tumor, the 3D volume of
interest A50 (VOIA50). This method is similar to the fixed
threshold method, except that it adapts the threshold relative to
the local average background, thereby correcting for the contrast
between tumour and local background. For example, the A50
contour value corresponds to a value at 50% of the sum of the
maximum voxel value and the local background value. The latter
value is derived from ‘background’ voxels that are identified as
those voxels located on a single voxel thick shell at 2.5 cm from the
edge of a 70% of maximum pixel value isocontour, excluding all
voxels with an SUV larger than 2.5.
SUV’s were normalized for body weight. For data-analysis, we
used early (2 min p.i.) and late (30 min p.i.) SUVmax and
SUVmean, as well as their absolute [SUV late - SUV early] and
relative differences [(SUV late - SUV early)/SUV early].
Furthermore, based on literature [8], we considered two
possible time-trends of [18F]FCH uptake by comparing the SUV
early and the SUV late: type A pattern (decreasing over time) if the
SUV early . the SUV late and type B pattern (stable/increasing
Table 2. SUV metrics of lymph nodes as a function of time.
Standard Uptake Value Benign Malignant Total
(SUV) N= 17 N= 37 N= 54
Maximum
Early (2 min p.i.)
Median 2 3.5 3
(Range) (1.4–8.4) (1.4–10) (1.4–10)
Late (30 min p.i.)
Median 1.4 4.3 3.2
(Range) (0.95–4.8) (2.2–11) (0.95–11)
Difference
Median 20.64 0.44 0
(Range) (23.6– 20.08) (21.4–3.8) (23.6–3.8)
Relative Difference
Median 20.32 0.084 0
(Range) (20.54– 20.055) (20.25–1.4) (20.54–1.4)
MeanA50
Early (2 min p.i.)
Median 1.5 2.6 2.3
(Range) (1.1–5.6) (1.2–7.2) (1.1–7.2)
Late (30 min p.i.)
Median 1.1 3.4 2.6
(Range) (0.75–3.4) (1.8–8.1) (0.75–8.1)
Difference
Median 20.42 0.31 0.03
(Range) (22.2–0.02) (21–2.7) (22.2–2.7)
Relative Difference
Median 20.29 0.11 0.013
(Range) (20.49–0.019) (20.22–1.4) (20.49–1.4)
Difference = SUVlate – SUVearly.
Relative difference = (SUVlate – SUVearly)/SUVearly.
doi:10.1371/journal.pone.0048430.t002
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over time) if the SUV late was equal or exceeded the SUV early.
Equality of SUV’s was decided using the 2nd decimal. In the
present context, accuracy measures relate to the ability of time-
trends (2 versus 30 min p.i.) of tracer uptake to discriminate
malignant and benign lymph nodes with enhanced [18F]FCH
uptake.
Statistical Analysis
The two sample Mann-Whitney tests were performed to
determine a shift in the median values for benign and malignant
tumors. Linear mixed-effects models were constructed to deter-
mine the relation between SUVmax and SUVmean. Included in this
model were tumor status (benign versus malignant) and post
injection scan time (2 min versus 30 min) as fixed effects, as well as
random slopes per patient and per lesion (nested within patient).
The residuals were assumed to be exponential related to SUVmean,
and pairwise interactions between SUVmean and both tumor status
and scan time were also tested. An identical linear regression
model ignoring repeated measures and heteroscedasticity was used
to provide an R2. Receiver Operating Characteristic (ROC)
curves were constructed to determine the thresholds maximizing
specificity and sensitivity. The binomial distribution is used to
determine 95% confidence intervals of the sensitivity and
specificity estimates for the optimal thresholds. To ensure that
these results are not influenced by within-patient correlations in
uptake, a Monty Carlo process is performed where ROC curves
are produced for 500 datasets randomly generated so that each
patient has only one lesion. The range of the sensitivities and
specificities of the optimal thresholds from these ROC curves were
visually compared with the sensitivities and specificities calculated
using all observations.
Results
We identified 25 eligible patients who had 54 lymph nodes with
enhanced [18F]FCH uptake that met our inclusion criteria. In 13/
Figure 1. Comparison of SUVmax and SUVmeanA50. a Early = 2 min p.i.; b Late = 30 min p.i.; c Difference= SUVlate – SUVearly; d Relative
difference= (SUVlate – SUVearly)/SUVearly. At the early scan time point, SUVmax = 1.40*SUVmean –0.07(Benign) –0.27(Malignant); versus a reduction of
20.07 in the intercept at the late (30 min p.i.) assessment.
doi:10.1371/journal.pone.0048430.g001
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25 (52%) patients the PET-CT had been performed because of
PSA relapse (I1), and in 9/25 (36%) for staging at presentation (I2);
the remaining three patients had been referred for restaging in the
context of presumed oligometastases (I3). The mean interval
between the primary therapy and the time of referral to [18F]FCH
PET-CT was 23 months (range: 3–48 months). In 17 patients
(pelvic group; median age: 63 years; range: 50–80 years) we found
34 enlarged pelvic nodes (classified as malignant, see methods),
and there were 7 patients (inguinal group; median age: 63 years;
range: 57–68 years) with 15 [18F]FCH positive inguinal LN,
classified as benign. One patient had enhanced [18F]FCH uptake
in both two inguinal and three enlarged pelvic nodes. In either
group the median number of eligible lymph nodes per patient was
2 (range: 1–6). Patient characteristics are presented in Table 1.
All LN showed enhanced FCH uptake at early (2 min p.i.) as
well as late (30 min p.i.) time points (Table 2). The long axes of the
inguinal and pelvic lymph nodes were similar (1162, and
1263 mm, respectively); short axis diameters were slightly smaller
in the former group (861 vs. 1062 mm, respectively; P,0.001).
We found highly significant associations between the LN status
(inguinal/benign vs. enlarged pelvic/malignant) and the SUVmax
and SUVmeanA50 30 min p.i., and their absolute and relative
differences (P,0.0001). The correlation between the mean and
max SUV metrics was near-perfect (Fig. 1; the linear regression
model resulted in an almost identical relation and an adjusted R2
of 0.99). For further analyses we focused on the SUVmax. The
number of LN with a [18F]FCH uptake pattern type A (SUVearly
. SUVlate) or B (SUVearly # SUVlate), in the benign and
malignant group for the above mentioned thresholds are included
in Table 3. Based on the SUVmax relative difference, all but one
LN in the benign group showed a type A, decreasing uptake over
time, while in the malignant group 95% (35/37) of the nodes
presented a type B pattern uptake. From the 54 LN, only 3 nodes
were found to have a stable uptake over time: one from the
inguinal and two from the pelvic group, respectively.
ROC analyses of uptake trends over time and of SUV’s at either
time-point (Fig. 2) showed that the SUVmax relative difference was
the best predictor of the lymph node status, followed by the
SUVmax late and the SUVmax absolute difference [see also Table 3
for the areas under the ROC curve (AUC)]. The threshold of
SUVmax relative difference that maximized both sensitivity and
specificity was 20.19, for a sensitivity of 95% (95%CI 82–99) and
a specificity of 94% (95%CI 71–100), versus a SUVmax late
threshold of 2.3, for a sensitivity of 92% (95%CI 78–98) and a
specificity of 88% (95%CI 64–99).
In the 17 patients with 34 enlarged [18F]FCH positive pelvic
nodes, histopathological confirmation was obtained in 4 (11 LN);
all had type B time trends at [18F]FCH PET-CT. During follow-
up, 3 patients (6 LN) had radiological nodal progression; from
these five LN had a type B pattern and one LN proved to be false
negative: type A trend and radiological progression. In 3 other
patients, with only pathologically enlarged pelvic lymph nodes
(6 LN) to explain an elevated PSA and with a type B pattern, PSA
normalized upon therapy, accompanied by shrinkage of these
nodes. PSA decrease and disappearance of a solitary (type B) pelvic
node was observed in another patient who was treated with pelvic
radiotherapy that focused on a suspected recurrence in prostate
and this lymph node.
Six other patients (with 9 type B and 1 type A pelvic lymph
nodes) were treated with systemic therapy, because of local
recurrence and/or skeletal metastases. Finally, the patient with
both 2 inguinal and 3 pelvic LN (type A in the inguinal and type B
in the pelvic nodes) was treated with RT (prostate) and ADT
because of confirmed bone oligometastases at presentation. In
these 7 patients, PSA decreased over time and radiological
regression of all 13 enlarged pelvic nodes together with stable
dimensions of the inguinal nodes were recorded, as well. However,
this did not unequivocally confirm the LN status due to the use of
systemic therapy for coexistent bone metastases.
Of the inguinal nodes (14 type A and 1 type B with stable
uptake over time) none showed signs of malignancy during follow-
Table 3. Optimal thresholds for different SUV measures.
Standard Uptake Value (SUV) Threshold
Pattern
type Ben Mal
Sensitivity
(95% CI)
Specificity
(95% CI)
AUC
(95% QR)
SUVmax
Late (30 min p.i.) 2.32 A 15 3 92 88 0.93
B 2 34 (78–98) (64–99) (0.88–0.94)
Difference 20.31 A 16 6 84 94 0.90
B 1 31 (68–94) (71–100) (0.87–0.97)
Relative Difference 20.19 A 16 2 95 94 0.98
B 1 35 (82–99) (71–100) (0.95–0.99)
SUVmeanA50
Late (30 min p.i.) 1.66 A 15 0 100 88 0.95
B 2 37 (91–100) (64–99) (0.91–0.95)
Difference 20.18 A 16 7 81 94 0.89
B 1 30 (65–92) (71–100) (0.84–0.98)
Relative Difference 20.15 A 16 3 92 94 0.97
B 1 34 (78–98) (71–100) (0.92–0.99)
Pattern type: A= SUVearly . SUVlate; B = SUVearly # SUVlate.
Ben benign, Mal malignant, CI confidence interval, AUC area under the ROC curve, QR quartile range.
Difference = SUVlate – SUVearly.
Relative difference = (SUVlate – SUVearly)/SUVearly.
doi:10.1371/journal.pone.0048430.t003
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up; of these, in one patient a lymph node biopsy was tumor
negative. One patient (2 LN) opted for watchful waiting policy
(otherwise negative PET), and his PSA was stable at 0.4 ng/ml for
the follow-up of 12 months. In another patient (type A LN) a local
recurrence was treated with HIFU with good clinical response
(PSA) and no signs of progression.
Discussion
In our referral-based spectrum of patients with enhanced
[18F]FCH uptake in pelvic and inguinal lymph nodes, decreasing
[18F]FCH uptake over time seems to be a reliable tool to
differentiate benign and malignant nodes. Together with similar
findings by others to classify radioactive choline positive lesions
suspected to represent hematogeneous metastases, our results are
relevant for clinical decision making and simplification of
diagnostic procedures, eg. in patients with elevated PSA and
positive [18F]FCH PET findings. Moreover, the results underline
the relevance of a sequential PET imaging protocol after a single
injection of [18F]FCH to account for the time-trend of tracer
uptake.
Figure 2. ROC analyses and Treshold boxplots. a ROC analyses of SUVmax 30 min p.i. assessment (late), difference (SUVlate – SUVearly) and
relative difference [(SUVlate – SUVearly)/SUVearly]. The grey lines represent the 500 ROC curves for randomly generated datasets in which only one
lesion is included for each patient; the blue lines are the ROC curves for all 54 lesions; the red lines indicate the shortest distance to the top left hand
corner; b Threshold boxplots. Thresholds associated with the shortest distance to the top left hand corner in the ROC curves are indicated in the
boxplots by the horizontal red lines.
doi:10.1371/journal.pone.0048430.g002
Dual-Phase [18F]FCH PET-CT in Prostate Cancer
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e48430
We classified disease-status as malignant for enlarged pelvic
nodes, and as benign for inguinal nodes of any size. Our criterion of
benignity was based on the typical prostate drainage pattern which
does not include inguinal nodes, as described by Inoue et al. [20].
They identified by using fluorescence navigation 3 lymphatic
drainage pathways, comprising the obturator, the external and
internal iliac nodes. Similar drainage patterns were found by
Tokuda et al. [21] in 125 patients with LN metastases. Weck-
ermann et al. [22] performed both sentinel lymph node dissection
and radical prostatectomy in 1055 patients with PCa. Despite a
high percentage (.50%) of positive nodes identified outside the
standard lymphadenectomy borders, none of them were found in
the inguinal region. In our study we also never encountered
occurrences of malignancy in inguinal nodes (histological analysis,
clinical radiological follow-up).
We considered pelvic nodes with a short axis diameter equal or
exceeding 8 mm as being malignant. This threshold was chosen
based on the study of Jager et al. [23] who reported a 98%
specificity for MRI using this dimension. In their meta-analysis,
Ho¨vels et al. [31] found that false positivity of CT/MRI (similar
performance for either technique) at thresholds of 8–10 mm is
only 7%. In an attempt to reduce the remaining uncertainty, a
standard of reference method was used. This approach, as
extensively described in the ‘‘Materials and Methods’’ section,
Figure 3. Example of decreasing [18F]FCH uptake over time. Example of decreasing [18F]FCH uptake over time in a right inguinal lymph
node (red arrow; SUVmax early: 4.41; SUVmax late: 2.03) of a patient with newly diagnosed prostate cancer. This lymph node was classified as benign.
Transversal sections of the Low-dose CT, PET and fused PET-CT images: a, b and c – early phase; d, e and f – late phase. [18F]FCH uptake in the
prostate is also visible.
doi:10.1371/journal.pone.0048430.g003
Figure 4. Example of increasing [18F]FCH uptake over time. Example of increasing [18F]FCH uptake over time in a right para-iliac lymph node
(red solid arrow; SUVmax early: 3.02; SUVmax late: 4.35) and a left para-iliac node (red dotted arrow; SUVmax early: 3.47; SUVmax late: 4.79) of a patient
with biological relapse after initially treated prostate cancer. These lymph nodes were classified as malignant. Transversal sections of the Low-dose
CT, PET and fused PET-CT images: a, b and c – early phase; d, e and f – late phase.
doi:10.1371/journal.pone.0048430.g004
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consisted of the combination of histopathological examination
(whenever available) and the results obtained by clinical or
radiological follow-up. This is a commonly used procedure [32–
37] to account for the limitations of retrospective studies. In
difficult cases, biopsy of the proper radioactive choline avid lymph
nodes was improved and verified by using a dedicated gamma-
probe [38]. Confirmation seemed feasible in 65% of these pelvic
LN (24/37). In 7 patients treated with ADT and/or chemother-
apy for coexisting bone metastases, decreases of nodal diameter
could not be interpreted since such changes are not necessarily
compatible with a ‘malignant tissue’ response to treatment.
Note that in our present context ‘sensitivity’ and ‘specificity’
should not be confused with ‘the accuracy of [18F]FCH PET-CT
to diagnose metastatic lymph nodes in prostate cancer’. The
results pertain to the ability of tracer uptake time-trends to classify
lymph nodes with enhanced [18F]FCH uptake.
The relevance of uptake time-trends to characterize [18F]FCH
foci has been demonstrated in malignant bone metastases, in
recurrent PCa, and in malignant zones of the prostate in
preoperative setting [8,15,17]. Our findings corroborate and
extend those of Beheshti et al. [8] who reported on 18 malignant
lymph nodes showing stable or increasing uptake over time. The
imaging protocol consisted of a dynamic PET/CT scan of the
pelvic region for 8 min, starting 1 min p.i., followed by whole
body (WB) images 10 min after [18F]FCH injection and optional
supplementary delayed WB acquisitions, 90–120 min p.i., when
abnormalities were detected. However, since that study comprised
only 4 [18F]FCH positive reactive lymph nodes (with decreasing
uptake over time) they urged for validation of these patterns in a
larger study.
In our study, all but one inguinal nodes showed decreasing
[18F]FCH uptake over time (Fig. 3), versus 95% (35/37) of the
pelvic category demonstrating stable or increasing uptake (Fig. 4).
Kwee et al. [15] suggested as a possible explanation for the tracer
decrease over time in benign zones the dephosphorylation of
[18F]FCH by prostatic acid phosphatase while a trapping
mechanism of the tracer in the malignant cells was responsible
for the increased uptake in PCa. This can only be validated with
full kinetic modeling.
Our results are at variance with those of Cimitan et al. [15] who
reported no significant late/early [18F]FCH uptake ratios in
proven local recurrent prostatic disease or abdominopelvic LN,
when performing a dual phase [18F]FCH PET-CT in 43 patients
with PSA relapse. However, their dual-phase PET/CT protocol
included WB scans with variable early and late acquisitions, 5 to
15 min p.i. and 65 to 200 min p.i., respectively. The discrepancy
may be explained by the rapid clearance of the [18F]FCH after
administration [14,16], which implies that timing of the early
acquisitions is crucial and should be done using a strict imaging
protocol.
The prevalence of patients with inguinal lymph nodes showing
enhanced [18F]FCH uptake was 12% (8/66 patients). Our finding
that reactive nodes remained detectable over time (i.e., for 30 min.
after injection) seems being inconsistent with the observation of
Price et al. [16] who found persistent uptake at the late, 45 min
p.i., images in only 1 of 4 patients with initially enhanced inguinal
node uptake. We content that this variance results from improved
signal to noise ratios with the current TOF scanner generations.
Our data suggest that the type B pattern is a strong indication
for malignancy, the PPV being 97% (35/36; see Table 3, for the
best LN status predictor: SUVmax Relative Difference). The fact
that the PPV is not 100% implies in clinical practice that, e.g. in
case of multiple potentially malignant [18F]FCH positive LN, the
ones with type B patterns should be the primary biopsy candidates.
Our results also suggest that a single point measurement in the
context of a whole body scan, starting in caudocranial direction,
30 min after injection, is a reasonable alternative for relative
change to differentiate reactive from malignant LN in patients
with PCa. Obviously, omitting the early scan would simplify the
scan procedure. However, compared to measuring relative
changes, the use of absolute SUV’s is more demanding at the
level of standardization. Evidently, the present results pertain to
lymph nodes with enhanced [18F]FCH uptake and $8 mm short
axis. Ascertaining the single time-point approach requires
validation versus histopathology.
Conclusion
Time-trends of enhanced [18F]FCH uptake in lymph nodes of
prostate cancer patients seem to help discriminate benign from
malignant localizations. Single time-point SUV measurements,
30 min p.i., may be a reasonable alternative for predicting the
nodal status, but this remains to be validated in non-enlarged
pelvic lymph nodes.
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